Sarepta Therapeutics (SRPT)

[FinancialAdvisor]

It actually closed slightly up in the after-hours so the proposed offering seems to have already been priced in. And with this accumulation that has gone on today and yesterday in the stock, it suggests that this is not only still potentially undervalued but also a takeover candidate. Also interesting to note that while they're proposing the sale of around 4 million shares of stock at an assumed price around $56/share; keep in mind the short interest in this stock is nearly 4x that.

It would not surprise me to see this stock squeeze higher to close out the week. I think it benefits the big parties involved such as Goldman Sachs and JP Morgan as they make commission off of any sales of securities, so the higher they could pump the price, the more they would make. They also would benefit from a takeout should they still have shares in their inventory.